Malignant Melanoma

Oncology·MeSH: Melanoma

Prevalence

75.0 / 100K

Incidence

23.0 / 100K/yr

6 drugs in development·3 companies·5 clinical trials

Drug Pipeline by Phase

Phase 3(2)

Drug	Company
Lenvatinib	Merck & Co., Inc. (MRK)
V940	Merck & Co., Inc. (MRK)

Phase 2(2)

Drug	Company
ot-101	Oncotelic Therapeutics, Inc. (OTLC)
thor-707	Sanofi (SNY)

Phase 1/Phase 2(2)

Drug	Company
cemiplimab	Sanofi (SNY)
Cemiplimab	Sanofi (SNY)

BioSniper tracks 6 drugs in development for Malignant Melanoma across 3 companies.

There are 5 clinical trials targeting Malignant Melanoma tracked by BioSniper.

The estimated prevalence of Malignant Melanoma is approximately 75.0 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.